Shares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, ...

The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid funding, ...

The Handmaid's Tale season 6 will depict the greatest rebellion against Gilead yet. The season is poised to serve as the show ...

Live Updates Live Coverage Updates appear automatically as they are published. No Where to Hide 10:13 am The markets are ...

The move: Gilead Sciences dropped 2.52% in premarket trading, falling to $107.45 per share Wednesday morning. The biopharmaceutical company is up 19.34% for the year. Why: The stock's decline ...

Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...

--Up 43.68% from 52 weeks ago (March 20, 2024), when it closed at $73.98 --Down 9.47% from its 52-week closing high of $117.41 on March 7, 2025 --Up 68.32% from its 52-week closing low of $63.15 ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

A new study published has revealed that Gilead Sciences’ Lenacapavir has shown promising results as prevention method for HIV with long-lasting effects. The annual injection can be used as a pre ...

Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the drug.

Gilead said two ex­per­i­men­tal once-a-year ver­sions of its HIV pre­ven­tion shot lenaca­pavir passed muster in an ear­ly-stage study with a small group of healthy par­tic­i­pants … ...